Celldex Therapeutics (CLDX) vs Neogen (NEOG)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Neogen (NEOG) has outperformed Celldex Therapeutics (CLDX) over the past year, gaining 108.9% versus a gain of 7.6%. Over five years, CLDX leads with a -36.6% price change compared with -71.5% for NEOG. Neogen is the larger company by market cap ($2.55 billion vs $2.30 billion), about 1.1 times the size.
Neogen converts more of its revenue into profit, with a net margin of -0.9% versus -16748.0%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CLDX | NEOG |
|---|---|---|
| Share price | $29.30 | $11.71 |
| Market cap | $2.30B | $2.55B |
| 1-day change | -3.71% | +0.26% |
| YTD return | +7.88% | +67.10% |
| 1-year return | +7.56% | +108.94% |
| 5-year return | -36.55% | -71.54% |
| Forward P/E | — | 30.82 |
| EPS (TTM) | $-4.35 | $-0.26 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $1.54M | $870.40M |
| Revenue growth (YoY) | -77.99% | -2.72% |
| Net income (latest FY) | $-258.76M | $-7.90M |
| Gross margin | 87.06% | 46.93% |
| Operating margin | -18599.81% | -2.48% |
| Net margin | -16748.03% | -0.91% |
| 52-week high | $45.14 | $14.26 |
| 52-week low | $22.10 | $5.37 |
| Distance from 52-week high | -35.09% | -17.88% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +115.26% | +19.56% |
| Average volume | 1.27M | 3.02M |
| Shares outstanding | 78.53M | 218.11M |
| Employees | 198 | 2,636 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NEOG has outperformed CLDX by 101.4 percentage points over the past year.
- Neogen is more profitable, keeping -0.9 cents of every revenue dollar as net income versus -16748.0 cents for Celldex Therapeutics.
- Neogen grew revenue faster in its latest fiscal year (-2.72% vs -77.99%).
About Celldex Therapeutics
CLDX stock →Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases. The company's drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 198 employees
About Neogen
NEOG stock →Neogen Corporation develops, manufactures, and markets various products and services for food and animal safety in the United States and internationally. It operates through Food Safety and Animal Safety segments.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 2,636 employees
CLDX vs NEOG FAQ
Which is bigger, Celldex Therapeutics or Neogen?
Neogen (NEOG) is larger, with a market capitalization of $2.55B compared with $2.30B for Celldex Therapeutics (CLDX).
Which stock has performed better over the past year, CLDX or NEOG?
NEOG returned +108.94% over the past 12 months, compared with +7.56% for CLDX (price return, excluding dividends). Past performance does not predict future results.
Are Celldex Therapeutics and Neogen in the same industry?
Yes. Both are classified in the Biotechnology: In Vitro & In Vivo Diagnostic Substances industry within the Health Care sector.